English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Type 2 diabetes mellitus consists of an array of dysfunctions characterized by hyperglycemia and resulting from the combination of resistance to insulin action, inadequate insulin secretion, and excessive or inappropriate glucagon secretion. The A1C test is a blood test that provides information about a person’s average levels of blood glucose, also called blood sugar, over the past 3 months. The Aim is to study roll of HbA1c as screening biomarker of dyslipidemia in Type 2 Diabetes mellitus patients. The Study consists of 120 type 2 DM patients of 40-70 year age group along with age and sex matched healthy control. Fasting Blood samples were collected from all participants for measurement of Lipid profile, Blood sugar (FBS) and HbA1c. In case group, the mean concentration of Fasting blood glucose (mg/dl), S.Cholestrol (mg/dl), S.Triglyceride (mg/dl), S.HDL(mg/dl) and HbA1c(%) is 138.5±5.2, 265±10.5, 210.9±5.2, 38.6±6.3 and 10.6±1.0. Respectively while in control group it is 85.6±6, 156.9±8.5, 119.5±7.3, 44.5±3.2 and 5.2±0.5 respectively. The HbA1C might be used as a reliable biomarker in the screening of dyslipidemia in diabetes type2 patients because it showed positive correlation with TC, TG, VLDL, and LDL-C but negative correlation with HDL-C.

HbA1c is a biomarker of dyslipidemia in T2DM patients